Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction
Sponsor: Emmecell
Summary
This study will evaluate the safety and effectiveness of a single injection of EO2002 at one of two dose levels (150,000 or 500,000 magnetic human corneal endothelial cells \[mHCECs\]), compared with a placebo injection, in participants with corneal edema caused by corneal endothelial dysfunction.
Official title: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 2 Study of EO2002 in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction (EMERALD)
Key Details
Gender
All
Age Range
21 Years - Any
Study Type
INTERVENTIONAL
Enrollment
121
Start Date
2026-10
Completion Date
2028-02
Last Updated
2026-10-09
Healthy Volunteers
No
Conditions
Interventions
150K cells
Intracameral injection - 150K dose
500K cells
Intracameral injection - 500K dose
Placebo
Intracameral injection of vehicle
Locations (10)
Torrance, California
Torrance, California, United States
Largo, Florida
Largo, Florida, United States
Atlanta, Georgia
Atlanta, Georgia, United States
Chicago, Illinois
Chicago, Illinois, United States
Carmel, Indiana
Carmel, Indiana, United States
Overland Park, Kansas
Overland Park, Kansas, United States
Minnetonka, Minnesota
Minnetonka, Minnesota, United States
Kansas City, Missouri
Kansas City, Missouri, United States
Garden City, NY
Garden City, New York, United States
Salt Lake City, Utah
Salt Lake City, Utah, United States